Pargluva won’t launch within next two years, Bristol-Myers Squibb says

Share this article:
Bristol-Myers Squibb said its diabetes drug Pargluva (muraglitazar) won't be launched in 2006 or 2007, The Wall Street Journal reported today.
In the newspaper report, the company said it still has not decided whether it will pursue marketing approval for Pargluva and likely won't make a decision before next year.
Pargluva is the first drug in what had been considered a promising new class of drugs for millions of diabetics.
In October, researchers released data indicating that use of the drug more than doubles the risk of life-threatening cardiovascular complications.
The Cleveland Clinic researchers, who also pointed out the heart risks of Vioxx in 2001, said the agency should not approve the drug until additional research is conducted.
Also in October, the FDA issued an approvable letter, indicating the drug could be cleared for marketing once additional information to be provided by BMS is received and reviewed.
Bristol-Myers Squibb said it could take five years to obtain this additional data and that the company was considering a range of options, including additional studies or terminating further development. "We're still convinced that this is an important product," Lamberto Andreotti, president of the company's worldwide pharmaceuticals division, told The Journal adding that the company remains in discussions with the FDA over Pargluva.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Judge blocks FDA bid to allow generic Precedex

Judge blocks FDA bid to allow generic Precedex

The US District Court for Maryland granted Hospira a temporary restraining order (TRO) against FDA, after the agency determined that potential generic competitors of the company's injectable sedation drug Precedex ...

GSK drug gets aplastic anemia indication

GSK drug gets aplastic anemia indication

Promacta was previously indicated for chronic immune thrombocytopenia.

Five things for Pharma Marketers to know: Wednesday, August 27

Five things for Pharma Marketers to know: Wednesday, ...

Allergan sets a shareholder voting date, Novo describes the types of acquisitions it will consider, and the AstraZeneca-Pfizer talks can now reopen.